Use of topical glucocorticoids: a population-based cohort study.

J Eur Acad Dermatol Venereol

Department of Dermatology, Henri Mondor hospital, Paris, France.

Published: June 2017

Background: Little is known about the prescriptions of topical glucocorticoids in the general population.

Objectives: To report an overall picture of topical glucocorticoid prescriptions in France.

Methods: This study used the Echantillon Généraliste de Bénéficiaires (EGB) database, a 1/97th random sampling of the French population covered by the main national healthcare insurance system (approximately 90% of the whole population). All patients prescribed topical glucocorticoids over a 5-year period (1 January 2011 to 31 December 2015) were identified using a specific code list for topical glucocorticoids.

Results: Over the 5-year study period, 662 531 individuals were recorded for at least 1 day in the EGB. Among them, 220 345 (33.3%) were prescribed at least once topical glucocorticoid. The prevalence of topical glucocorticoid prescription increased regularly from 2011 (11.7%) to 2015 (12.5%). A total of 922 026 tubes of topical glucocorticoids were dispensed, mainly high-potency glucocorticoids, and were mainly prescribed by general practitioners (73.1%). A total of 1713 (0.8%) patients were prescribed at least 24 tubes over a calendar year. These patients were more frequently men (P < 0.001) and older (P < 0.001) than the overall population of patients prescribed topical glucocorticoids. The 124 844 tubes prescribed to these patients had stronger potency than those prescribed to the overall population (P < 0.001) and were mostly prescribed by general practitioners (68.1%). The reasons for prescription were available for only 371 patients (21.7%) and were mainly psoriasis, auto-immune bullous dermatoses and eczema.

Conclusion: About 12% of the French general population is prescribed topical glucocorticoids at least once each year. Most prescriptions are issued by general practitioners, dermatologists being the prescribers in less than one-quarter of cases.

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.14149DOI Listing

Publication Analysis

Top Keywords

topical glucocorticoids
24
prescribed topical
16
topical glucocorticoid
12
patients prescribed
12
general practitioners
12
topical
10
prescribed
9
population patients
8
prescribed general
8
glucocorticoids
6

Similar Publications

Hypertrophic scars (HTSs) are the result of an abnormal healing process resulting from burns and other severe traumas. The symptoms of that condition include skin irritation, discomfort, and itching. This study aimed to assess the efficacy of fractional carbon dioxide (CO) laser therapy alone or with triamcinolone or 5-fluorouracil (FU) in the treatment of early post-burn hypertrophic scars (HTSs) that develop during the first 6 months after the injury.

View Article and Find Full Text PDF

[Local injections of glucocorticoids at different regions in the treatment of sudden sensorineural hearing loss: a Meta-analysis].

Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

January 2025

Department of Pathology and Pathophysiology, School of Medicine, Nanjing University of Chinese Medicine, Nanjing210023, China.

To compare the efficacy and safety of postauricular injection (PI) and intratympanic injection (II) of glucocorticoids (GC) in the initial treatment of sudden sensorineural hearing loss (SHL). Electronic databases retrieval (PubMed, Web of Science, CNKI, VIP, WANFANG) was performed to identify all randomized controlled trials about PI and II of GC in the initial treatment of SHL between 2015 and 2024. Meta-analysis was performed on the studies met the inclusion criteria by RevMan5.

View Article and Find Full Text PDF

Considering the increasing use of immune checkpoint inhibitors in cancer treatment, our aim is to report a rare cutaneous immune-related adverse event induced by PD-1 inhibitor pembrolizumab and provide a brief overview of pembrolizumab-induced subacute cutaneous lupus erythematosus (SCLE) cases in the literature. We report a 67-year-old woman with oropharyngeal squamous cell carcinoma who developed SCLE during treatment with pembrolizumab. After 18 weeks (sixth cycle) of pembrolizumab immunotherapy, a widespread pruritic erythematous rash evaluated as grade 3 immune-related adverse event appeared primarily on the patient's limbs.

View Article and Find Full Text PDF

Feline Aural Inflammatory Polyps.

Vet Clin North Am Small Anim Pract

January 2025

VCA Aurora Animal Hospital, 2600 W Galena Boulevard, Aurora, IL, USA.

Feline aural inflammatory polyps originate from the tympanic bulla and less frequently from the auditory tube, representing the most common benign tumor of the feline ear. Clinical signs may be compatible with otitis externa, media, and/or interna with rare occurrences involving meningoencephalitis or abscessation of periauricular tissue. Traction and avulsion is an effective treatment procedure with a relatively low recurrence rate, especially when systemic glucocorticoids are given after polyp removal.

View Article and Find Full Text PDF

Topical formulations containing 5-Fluorouracil (5-FU) have been proven effective in preventing the proliferation of skin cancer cells. However, their use is linked to side effects such as inflammatory and allergic reactions. Dexamethasone (Dexa) is a synthetic glucocorticoid used across allergic reactions which can be useful in preventing the 5-FU side effects.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!